Sofie Declercq
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sofie Declercq has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Bradley D. Smith
Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA
1 shared publication - Dong-Hao Li
Department of Chemistry and Biochemistry University of Notre Dame 251 Nieuwland Science Hall Notre Dame IN, 46556 USA
1 shared publication Jan Brokemper
University of Helsinki A.I. Virtasen Aukio 1
1 shared publication- Jelena Saliën
Université Bourgogne Europe CNRS, Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB, UMR CNRS 6302) Dijon France
1 shared publication - Jessica Bridoux
Vrije Universiteit Brussel VUB Laarbeeklaan 103
1 shared publication Julie Du Ville
Vrije Universiteit Brussel─Molecular Imaging and Therapy Research Group (MITH)
1 shared publication
Latest Publications
- Open Access
- 16 November 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
Site-Specific Enzymatic Radiofluorination of Biomolecules: From Current Methodologies to Emerging Opportunities
The recent expansion of recombinant biomolecules as diagnostic and therapeutic agents has created a strong need for mild, site-specific, and universally applicable methods to radiolabel them for positron emission tomography (PET). Fluorine-18 is one of the most widely used radionuclides for PET because it combines a clinically practical half-life, high positron intensity with low mean energy, and a non-metallic footprint in the label. However, the conditions necessary for efficient nucleophilic fluorine-18 radiolabelingbasic, anhydrous media, elevated temperature, and aprotic solventsare poorly compatible with sensitive biomolecules. Therefore, prosthetic group labeling with subsequent conjugation, both site-specific and non-site-specific, and aluminum-[18F]fluoride (Al[18F]F2+) chelation have become essential workarounds. Depending on the radiolabeling site, this can yield heterogeneous products, with impaired tracer target binding and pharmacokinetics. Enzymatic ligation offers a complementary strategy, with radiofluorination done on a robust small-molecule or peptide substrate, and subsequently, an enzyme catalyzes a mild and site-specific conjugation to a genetically encoded recognition motif on the target. This ensures that each step proceeds under its own optimal conditions. This review evaluates the current state of enzymatic and chemoenzymatic radiofluorination of biomolecules, from the early fluorinase work to recent advances with lipoic acid ligase (LplA), peptide asparaginyl ligase, and sortase A (SrtA). It further reviews enzymes and techniques that could extend this toolbox. The field is still emerging, but available evidence suggests that enzyme-mediated radiofluorination can occupy a niche between classical prosthetic-group radiochemistry and kit-like radiometal labeling, especially for fragile recombinant biomolecules whose radiolabeling with fluorine-18 is currently a challenge.
- 16 November 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
Open AccessSite-Specific Enzymatic Radiofluorination of Biomolecules: From Current Methodologies to Emerging Opportunities
The recent expansion of recombinant biomolecules as diagnostic and therapeutic agents has created a strong need for mild, site-specific, and universally applicable methods to radiolabel them for positron emission tomography (PET). Fluorine-18 is one of the most widely used radionuclides for PET because it combines a clinically practical half-life, high positron intensity with low mean energy, and a non-metallic footprint in the label. However, the conditions necessary for efficient nucleophilic fluorine-18 radiolabelingbasic, anhydrous media, elevated temperature, and aprotic solventsare poorly compatible with sensitive biomolecules. Therefore, prosthetic group labeling with subsequent conjugation, both site-specific and non-site-specific, and aluminum-[18F]fluoride (Al[18F]F2+) chelation have become essential workarounds. Depending on the radiolabeling site, this can yield heterogeneous products, with impaired tracer target binding and pharmacokinetics. Enzymatic ligation offers a complementary strategy, with radiofluorination done on a robust small-molecule or peptide substrate, and subsequently, an enzyme catalyzes a mild and site-specific conjugation to a genetically encoded recognition motif on the target. This ensures that each step proceeds under its own optimal conditions. This review evaluates the current state of enzymatic and chemoenzymatic radiofluorination of biomolecules, from the early fluorinase work to recent advances with lipoic acid ligase (LplA), peptide asparaginyl ligase, and sortase A (SrtA). It further reviews enzymes and techniques that could extend this toolbox. The field is still emerging, but available evidence suggests that enzyme-mediated radiofluorination can occupy a niche between classical prosthetic-group radiochemistry and kit-like radiometal labeling, especially for fragile recombinant biomolecules whose radiolabeling with fluorine-18 is currently a challenge.
- 31 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 23472-23484
A Comparative Study on the Effect of Near-Infrared Fluorescent Dyes on the Pharmacokinetic Behavior of Nanobody-Based Tracers for In Vivo Imaging
Near-infrared fluorescent molecular imaging is increasingly being used as a tool to guide intraoperative decision-making. While research into novel fluorescent molecular tracers often prioritizes the targeting moiety, compelling evidence indicates that the choice of fluorophore can substantially influence tracer pharmacokinetics. In this study, tumor-specific Nanobodies were conjugated with four widely used dyes─IRDye800CW, ZW800-1, FNIR-Tag, and s775z-, and a side-by-side comparison of their in vivo biodistribution and tumor targeting was performed. Nanobodies labeled with FNIR-Tag or s775z showed markedly superior results compared to those labeled with IRDye800CW or ZW800-1, demonstrating strong tumor accumulation as early as 1 h postinjection and minimal background signal, particularly in the liver. The effect of increasing dye density on tracer pharmacokinetics was also assessed. Compared with Nbs labeled with a DOL of 1, those with an average of 2 dyes exhibited higher mean fluorescent tumor signals but no improvement in tumor-to-background ratios, owing to increased background signals.
- 31 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 23472-23484
A Comparative Study on the Effect of Near-Infrared Fluorescent Dyes on the Pharmacokinetic Behavior of Nanobody-Based Tracers for In Vivo Imaging
Near-infrared fluorescent molecular imaging is increasingly being used as a tool to guide intraoperative decision-making. While research into novel fluorescent molecular tracers often prioritizes the targeting moiety, compelling evidence indicates that the choice of fluorophore can substantially influence tracer pharmacokinetics. In this study, tumor-specific Nanobodies were conjugated with four widely used dyes─IRDye800CW, ZW800-1, FNIR-Tag, and s775z-, and a side-by-side comparison of their in vivo biodistribution and tumor targeting was performed. Nanobodies labeled with FNIR-Tag or s775z showed markedly superior results compared to those labeled with IRDye800CW or ZW800-1, demonstrating strong tumor accumulation as early as 1 h postinjection and minimal background signal, particularly in the liver. The effect of increasing dye density on tracer pharmacokinetics was also assessed. Compared with Nbs labeled with a DOL of 1, those with an average of 2 dyes exhibited higher mean fluorescent tumor signals but no improvement in tumor-to-background ratios, owing to increased background signals.